Details for New Drug Application (NDA): 207712
NDA 207712 describes AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, which is a drug marketed by Apotex, Padagis Israel, and Teva Pharms Usa Inc, and is included in three NDAs. It is available from four suppliers. Additional details are available on the AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE profile page.
The generic ingredient in AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE is azelastine hydrochloride; fluticasone propionate. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride; fluticasone propionate profile page.
The generic ingredient in AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE is azelastine hydrochloride; fluticasone propionate. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride; fluticasone propionate profile page.
Summary for 207712
| Tradename: | AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE |
| Applicant: | Apotex |
| Ingredient: | azelastine hydrochloride; fluticasone propionate |
| Patents: | 0 |
Pharmacology for NDA: 207712
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists Histamine H1 Receptor Antagonists |
Suppliers and Packaging for NDA: 207712
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE | azelastine hydrochloride; fluticasone propionate | SPRAY, METERED;NASAL | 207712 | ANDA | Apotex Corp. | 60505-0953 | 60505-0953-3 | 1 BOTTLE, SPRAY in 1 CARTON (60505-0953-3) / 120 SPRAY, METERED in 1 BOTTLE, SPRAY |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SPRAY, METERED;NASAL | Strength | 0.137MG/SPRAY;0.05MG/SPRAY | ||||
| Approval Date: | Apr 28, 2017 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
